| Zacks Company Profile for Matinas Biopharma Holdings, Inc. (MTNB : AMEX) |
|
|
| |
| • Company Description |
| Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Number of Employees: 3 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.03 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 302,796 shares |
| Shares Outstanding: 5.09 (millions) |
| Market Capitalization: $5.24 (millions) |
| Beta: 1.31 |
| 52 Week High: $9.60 |
| 52 Week Low: $0.47 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
17.05% |
12.66% |
| 12 Week |
71.67% |
44.39% |
| Year To Date |
101.96% |
89.14% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Jerome D. Jabbour - Chairman; Chief Executive Officer & President
Keith A. Kucinski - Chief Financial Officer
Keith Murphy - Director
Edward Neugeboren - Director
Robin L. Smith - Director
|
|
Peer Information
Matinas Biopharma Holdings, Inc. (GSAC)
Matinas Biopharma Holdings, Inc. (CASI)
Matinas Biopharma Holdings, Inc. (ALCD.)
Matinas Biopharma Holdings, Inc. (OMNN)
Matinas Biopharma Holdings, Inc. (CGPI.)
Matinas Biopharma Holdings, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 576810303
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
|
|
Share - Related Items
Shares Outstanding: 5.09
Most Recent Split Date: 9.00 (0.02:1)
Beta: 1.31
Market Capitalization: $5.24 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/13/25 |
|
|
|
| |
